Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels

Diabetes, Obesity and Metabolism

Volumn 17, Issue 8, 2015, Pages 809-812

  Sjostrom C D ^a   Hashemi, M ^a   Sugg, J ^b   Ptaszynska, A ^c   Johnsson, E ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dapagliflozin; SGLT2; Type 2 diabetes; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DAPAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER;

BLOOD PRESSURE; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; HUMAN; LETTER; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; META ANALYSIS; METABOLISM; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SODIUM-GLUCOSE TRANSPORT PROTEINS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84937817781     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12500     Document Type: Letter

References (14)

1. Landsberg L, Aronne LJ, Beilin LJ etal. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich) 2013; 15: 14-33.
2. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
3. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
4. Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 392-402.
5. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
6. Bolinder J, Ljunggren Ö, Kullberg J etal. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
7. Forxiga. Summary of product characteristics. European Medicines Agency, 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf. Accessed 3 April 2015.
8. Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014; 68: 682-691.
9. Sjöström CD, Lystig T, Lindroos AK. Impact of weight change, secular trends and ageing on cardiovascular risk factors: 10-year experiences from the SOS study. Int J Obes (Lond) 2011; 35: 1413-1420.
10. Bolinder J, Ljunggren Ö, Johansson L etal. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159-169.
11. Whaley JM, Tirmenstein M, Reilly TP etal. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012; 5: 135-148.
12. Beavers KM, Beavers DP, Nesbit BA etal. Effect of an 18-month physical activity and weight loss intervention on body composition in overweight and obese older adults. Obesity (Silver Spring) 2014; 22: 325-331.
13. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5-11.
14. Pi-Sunyer X, Blackburn G, Brancati FL etal. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-1383.